News & Updates

Show Multimedia Only
Youth-onset T2D patients at high risk of CVD, ESKD

Youth-onset T2D patients at high risk of CVD, ESKD

09 Jun 2022 byStephen Padilla

The risks of cardiovascular disease (CVD) and end-stage kidney disease (ESKD) are elevated twofold in individuals with youth-onset type 2 diabetes (T2D), which is partly caused by the greater burden of obesity and other metabolic risk factors in this population, relative to those with type 1 diabetes (T1D), according to a Hong Kong study.

09 Jun 2022
Is remote insulin pump training safe for youths with T1D?

Is remote insulin pump training safe for youths with T1D?

08 Jun 2022

Remote insulin pump training among young patients with type 1 diabetes (T1D) appears to be as safe as in-person training, suggest the results of a recent study.

08 Jun 2022
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

06 Jun 2022